Desferioxamine increases iron depletion and apoptosis induced by ara-C of human myeloid leukaemic cells

Br J Haematol. 1998 Aug;102(3):746-52. doi: 10.1046/j.1365-2141.1998.00834.x.

Abstract

We investigated whether changes in iron metabolism and the transferrin receptor (TRF-R) expression were involved in the antileukaemic effects of arabinoside cytosine (ara-C). Treatment with 100 nM ara-C for 48h reduced thymidine uptake and increased the surface expression of the TRF-R on leukaemic blasts derived from 13/16 (81%) patients and on the HL-60 and U-937 cell lines. Whereas intracellular non-haem iron was strongly depleted 24 h after ara-C addition, TRF-R up-regulation and recovery of intracellular non-haem iron concentration occurred together after a longer exposure of the cultured cells to the drug. Since iron is an essential regulator of cell proliferation we have evaluated the effects of the combination between ara-C and the iron chelator desferioxamine (DSF) on the growth of HL-60 and U-937 cells. We found that desferioxamine strongly potentiated the effects of ara-C on leukaemic cell growth inhibition and apoptosis. This is the first report of a positive interaction between ara-C and an iron chelator in terms of antileukaemic effects.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Antidotes / pharmacology*
  • Antimetabolites, Antineoplastic / metabolism
  • Antimetabolites, Antineoplastic / therapeutic use*
  • Apoptosis / drug effects
  • Cell Division / drug effects
  • Cytarabine / metabolism
  • Cytarabine / therapeutic use*
  • Deferoxamine / pharmacology*
  • Drug Interactions
  • Drug Synergism
  • HL-60 Cells
  • Humans
  • Iron / metabolism
  • Leukemia, Myeloid / drug therapy
  • Leukemia, Myeloid / metabolism*
  • Leukemia, Myeloid / pathology
  • Receptors, Transferrin / metabolism*
  • Tumor Cells, Cultured

Substances

  • Antidotes
  • Antimetabolites, Antineoplastic
  • Receptors, Transferrin
  • Cytarabine
  • Iron
  • Deferoxamine